Recently a molecular model was proposed lor the binding site of the antagonist 3M -)-/V-(2,3-dihydro-l-mediyl-2-oxo-5~phenyl-l H-1,4-benzodia/epine-3 s I) I // mdole 2-c^'hoxamide (deva/epide) on the cholecystokinin-A (CCK A) receptor (Van der Bent et al., 1994. Drug Design Discov. 12, 129 14X). Fifteen amino acids were identified, including hydrophilic ones such as Seru '\ Asivw and S e r'71\ that might interact with the caihoxamide moiety in deva/epide. To provide mutational evidence for this model, wild-type and mutant receptors (S139A, N349A and S379A) were transiently expressed and compared with respect to the ability of devazepide to inhibit binding of radiolabelled cholecystokinin <2(> 33)^peptkle amide (CCK^S) mid CCK-H-evoked (V 1 mobilization. The data presented suggest the involvement of the three residues in antagonist binding, although to a different extent. However, it does not seem likely that hydrogen bonds are the driving force in view of the relatively minor changes in receptor affinity and activity. £9 1997 Elsevier Science B.V.
Introduction
Receptors interacting with the cholecystokinin (CCK) and gastrin families of peptides are widely expressed throughout the gastrointestinal and nervous system (Wank, 1995) . Recent primary amino acid sequence deduction of various CCK receptor cDNAs has strengthened previous pharmacological evidence for the existence of two receptor subtypes, designated CCK s and CCK H, the latter being identical to the gastrin receptor, The CCK x receptor pre dominates in the gastrointestinal tract, whereas the C'CKj, receptor is predominantly distributed throughout the brain and spinal cord. The extensive regulatory role of CCK in the gastrointestinal tract has stimulated the interest in developing receptor ligands with (ant)agonistic modes of action for the treatment of several gastrointestinal disor ders (Wank, 1995) . Thus far, two CCKA receptor antago-Corrcsponding author. T e l: CM 24) V > 1 45X9 ; K i\: U C 24) 3544)525; e-mail; P. V V i I lo ms («■hioch.k un. ni nists, loxiglumide (Meyer et al., (989) and devazepide (3M -)-AM2,3-dihydro-l-methyl-2-oxo-5-phcnyI-l W-1,4benzodia/.epine-3-yl)-l //-indole-2-carboxaniide; Lidclle et al., 1989) , have entered clinical studies. However, caution should be taken since animal toxicity studies revealed that long-term treatment with devazepide may lead to serious side effects (Iversen et al., 1991) .
In order to provide a more rational approach towards the design of receptor antagonists, Van der Bent et al. (1994) previously built a bacteriorhodopsin-hased model of the membrane-embedded part of the CCKA receptor in which they identified a putative antagonist binding site on the basis of the structure-activity relationships and confor mational characteristics of the two parent classes of CCKA receptor antagonists, lorglumide and devazepide. The most prominent feature of the proposed antagonist binding site is the presence of a hydrogen acceptor, the existence of which is concluded from the observation that the affinity of devazepide is highly dependent on the presence of a hydrogen atom on the exoeyclic amide bond that connects the benzodiazepine and indole systems (Hvans et al., 1988) . Both replacement of this hydrogen by a methyl group and that of the entire amide bond by a methylene bridge results sion and/or immunocytochemistry. Briefly, CHO cells were cultured in Dulbecco's modified Engle's medium in an affinity loss of over 4 log units. Potential hydrogen (DMEM) supplemented with 10% (v /v ) [octal calf serum acceptors are Ser139 (H3), T hr132 (H3), Asn349 (H6), S er375 in a humidified atmosphere of 5% C 0 2 at 37°C. For transfection, CHO cells were grown to 70% confluency, trypsinized and transferred to a cuvette (3 X I0ft cells/300 |xl). The cells were electroporated (250 V, 960 |xF) in the (H7) and Ser379 (H7). Of these, Ser139, located nearly half-way helix 3 (H3) in the interior of the receptor pore, is the most likely candidate since attempts to dock devazepide with hydrogen bonds to Asn349, S er375 and S er379 presence of 20 jxg of pTEJ8 containing full-length wildfailed, whereas Thr132 was regarded as unlikely because of type or mutated CCKA receptor cDNA. Based on the ability of transfected cells to respond to a maximal concen tration of CCK-8 with an increase in cytosolic free calcium concentration we routinely obtained a transfection effi ciency of about 70%* Similar values were reached with the CCKb receptor and the histamine receptor. In initial stud ies using immunocytochemistry following transfection with a pSG5-derived vector expressing the extracellular part of CD45 containing a vsv-tag a considerably lower value of its location close to the extracellular end of the pore. Other o amino acids, which» because of their location within 4 A of the predicted docking site, form part of the putative antag onist binding site, are: Phe112, Phe13\ M et136, S er143, T rp181, Ser184, Leu232, Trp342, lie345, Leu372 and Tyr376, The present study aims to validate the proposed model for the antagonist binding site of the CCKA receptor. To this end Ser139, Ser379 and Asn349 were individually mu tated into Ala. Mutated receptors were transiently ex-30% was obtained. This suggests that receptor proteins can pressed in Chinese hamster ovary (CHO-K1) cells and the potency of devazepide to inhibit the binding of radiola belled cholecystokinin-(26~33)-peptide amide (CCK-8) and the increase in the intracellular Ca2+ concentration ([Ca24] ;) in response to CCK-8 was determined. The data presented suggest that the three residues are indeed in volved in antagonist binding. However, the relatively small changes in receptor affinity and activity disfavour a role for hydrogen bonds as a driving force.
Materials and methods

Mutagenesis o f CCKA receptor cDNA
Full-length cDNA encoding the rat CCK A receptor, truncated to within three nucleotides of the first in frame ATG (Yule et ah, 1993) and subcloned into the mam malian expression vector pTEJ8, was kindly provided by Dr. C.D. Logsdon (University of Michigan, Ann Arbor, MI, USA). Oligonucleotides for mutagenesis are 5'-
C T A C T T C A T G G G T A C C G C C G T G A G C G T T T -3 '
(S 139A), 5'-CCTACACCTCCGCCTGTGTGAACCC-CATCATC-3' (S379A) and 5'-ATCTTCAGCGCTG-CAGCCTGGCGG-3' (N349A). Mutations were introduced by the T7-GEN site-directed mutagenesis kit from US Biochemical (Cleveland, OH, USA) and confirmed by sequencing. For transfection, cDNA was subcloned into the Hm dlll and BamHI sites of the mammalian expression vector pTEJ8.
Transfection o f CHO cells with cDNA o f the CCKA receptor
Chinese hamster ovary (CHO)-Kl cells were trans fected with cDNA of the CCKA receptor essentially as described in 'Methods in Electroporation' (Bio-Rad). With this method, transfection efficiencies of 50% to 100% have already be detected at relatively low expression levels by virtue of their ability to efficiently stimulate second mes senger production, whereas considerably higher expression levels are needed for immunocytochemical detection.
Fluorescence measurements in individual CHO cells
Transfected cells were grown for 24 h, trypsinized and seeded on a glass coverslip (2 X 10*1 cells/30 fil). The cells were allowed to attach for 30 min. Culture medium was added and the cells were grown to subconfluency for 24 h. For fluorescence measurements, the cells were incu bated with 2 jxM l-[2-(5-carboxyoxazol-2-yl)-6-aniinobenzofuran-5-oxy]-2-(2'-amino-5'-methylphenoxy)-ethane-jV, N, N \ N'-tetraacetic acid pentaacetoxy methylester (fura-2/AM) for 30 min at 37°C. To remove non-hydrolysed dye, cells were washed 3 times with a physiological salt solution containing 137 mM N aC l 4.7 mM KC1, 0.56 mM MgCU, 1.28 mM CaCU, 1.0 mM Na2HP04, 2 mM L-glutamine, 5.5 mM P-glucose, 0.1% (w /v ) bovine serum albumin and 10 mM HEPES (pH 7.4). Coverslips were mounted in a thermostatic (34°C) perfusion chamber, placed on the stage of an inverted microscope (Nikon Diaphot). Superfusion was at a How rate of I ml/ min. Routinely, an epifluorescent 40 X magnification oil im mersion objective was used to allow simultaneous monitor ing of an average of close to 80 individual cells. Dynamic video imaging was carried out as described previously (Willems et al., 1993a) using the MagiCal hardware and TARDIS software provided by Joyce Loebl (Dukesway, Team Valley, Gateshead, UK). The fluorescence emission ratio at 492 mn was monitored as a measure of [Ca2+]j after excitation at 340 and 380 nm.
Fluorescence measurements in suspensions of CHO cells
Transfected CHO cells were seeded in 25 cm2 culture been reported in CHO cells as judged from (i-gal expres-flasks (1 X 10ft cells/flask) and grown for 48 h. The cells were trypsinized and washed twice in a HEPES/Tris medium containing 133 mM NaCl, 4.2 mM KC1, 1.0 mM CaCl2, i.O mM MgCK, 5.8 mM glucose, 0.2 m g/m l soybean trypsin inhibitor, an amino acid mixture according to Eagle, 0.1% (w /v ) bovine serum albumin and 10 mM HEPES, adjusted with Tris to pH 7.4. Cells were resus pended in HEPES/Tris medium containing 1% (w /v ) bovine serum albumin and loaded with 2 jxM fura-2/AM for 20 min at 37°C. Excess fura-2/A M was removed by washing the cells twice with H EPES/Tris medium con taining 0.1% (w /v ) bovine serum albumin. Cells were transferred to a cuvette placed in a Shimadzu RF-5000 spectrofluorophotometer equipped with a magnetic stirrer and a thermostated cuvette holder. Fluorescence measure ments were carried out at 37°C as described previously (Willems et al., 1993a,b) . The fluorescence emission ratio at 490 nm was monitored as a measure of the average [Ca2+]: after excitation at 340 and 380 nm.
maximal devazepide concentrations for the inhibition of [125I]CCK-8 binding were calculated by means of the nonlinear regression computer program InPlot (Graphpad Software for Science, San Diego, CA, USA).
Materials
Tissue culture medium and additives were purchased from Gibco BRL (Paisley, UK) and fura-2/A M from Molecular Probes (Eugene, OR, USA). Soybean trypsin inhibitor and CCK-8 were obtained from Sigma Diagnos tics (St. Louis, MO, USA) and devazepide (L~364,718) from Merck (Darmstadt, Germany). [,25I]CCK~8 (2200 C i/m m ol) was purchased from NEN Research Products (Boston, MA, USA) and G F /B filters from Whatman (Maidstone, UK). All other chemicals were of reagent grade.
Radioligand binding studies 3. Results
Transfected CHO cells, cultured for 48 h, were washed twice with 20 mM sodium phosphate buffer (pH 7.8). After scraping, the cells were rcsuspended in 50 mM Tris/HCl (pH 7.8) containing 0.3 m g/m l soybean trypsin inhibitor and freeze-thawed 3 times using liquid nitrogen. The suspension was centrifuged at I0 0 0 0 X # (Eppendorf minifuge) for I h at 4°C. The pellet was resuspended in 50 mM Tris/HCI (pH 7.8). Binding studies were performed as described previously (IJzerman and Melman, 1992) . Briefly, 100 juul of membrane suspension (40 |xg protein) were added to 300 jxl of an assay buffer containing (final concentrations) 3.75 mM MgCI2, 0.0375% ( w /v ) 3-[(3cholamidopropyl) dimethylammonio] l-propanesulfonate, 50 pM [125l]CCK-8, the indicated concentration of de vazepide (L-364.718) and 7.5 mM HEPES (pH 7.4) and incubated for 30 min at 37°C. The reaction was quenched by the addition of 1 ml of ice-cold 'stop solution' contain ing 5 mM MgCK and 10 mM HEPES (pH 7.4) followed by rapid filtration through pre-soaked Whatman G F /B filters. The filters were washed 3 times with 2 ml ice-cold stop solution and taken up in scintillation fluid. Radioactiv ity retained on the filters was determined by liquid scintil lation counting. Total binding and non-specific binding were determined with 0.1 pM and 0.1 fxM CCK-8, respec tively, Values presented are expressed as percentage of specific binding ([total binding] -[non-specific binding]).
2,6. Data analysis and statistics
The results presented are the mean ± S.E. of the num ber of experiments indicated in the text. Paired Student's /-tests were used to determine statistical differences (P < 0.05), Half-maximal CCK-8 concentrations for the recruit ment of individual cells in terms of Ca2+ mobilization and the increase in [Ca2+]s in suspensions of cells and half-
3,L Effect o f receptor mutations on the inhibition by devazepide o f the specific binding o f [ 125IICCK-8 to mem branes o f CHO cells transiently expressing the CCKA receptor
Devazepide inhibited specific binding of radiolabelled CCK-8 to wild-type membranes dose-dependently. The IC5() was calculated to be 0.96 nM (S.E. = 0.11; n = 5) ( Fig. 1) . Similarly, devazepide inhibited specific binding of [ l3iil]CCK-8 to membranes of the S139A and S379A mu tant with IC5() values of 1.33 nM (S.E, = 0.25; n = 5) and 0.73 nM (S.E. = 0.04; n = 5), respectively. Although the ]CCK-8 binding to membranes from CHO cells transiently expressing wild-type or mutant CCKA receptors by de vazepide. Membranes from CHO cells transiently expressing wild-type or mutant CCKA receptors were incubated with 50 pM [l25l]CCK-8 in the presence of various concentrations of devazepide for 30 min at 37°C, For each membrane preparation* specific binding, i.e. the difference between maximal binding in the presence of 0.1 pM CCK-8 and aspecific binding in the presence of 0.1 jjlM CCK-8, is set at 100%, to which all other values, after correction for aspecific binding, are related. # Significantly different from the mutant S379A receptor. 321' (1997) 93-99 difference between the latter two IC50 values is small, it is statistically significant. On the other hand, both values are not significantly different from that obtained with the wild-type receptor. Compared to wild-type membranes, specific labelling, expressed in cpm per mg of protein, with membranes from the mutant receptors S139A, S379A and N349A and mock-transfected cells amounted to = 4), 75.3% (S.E. = 5.0; n = 4), 118.0% (S.E. = 24.4; n 2 .6% (?? = 1) and 0.3% (S.E. = 1.0; n = 3), respectively. The low value obtained with the N349A mutant receptor suggests that affinity a n d /o r expression of this receptor is markedly reduced. No specific binding was observed with mock-transfected CHO-K1 cells.
R.L.L S'meets el al. / Euroircan Journal of Pharmacology
Effect o f receptor mutations on the inhibition by devazepide o f the recruitment o f CHO cells transiently expressing the CCK A receptor in terms o f CCK-8-evoked Ca2 + mobilization
CCK-8 evoked a rapid increase in [Ca2*^ in CHO-K1 cells transiently expressing the wild-type CCKA receptor (Fig. 2 ). CCK-8 increased the number of responding cells dose-dependently (EC50 = 78 pM) to a maximum of 68% (S.E. = 7.5, n = 5) reached with 10 nM CCK-8 ( Fig. 3,  upper left) . The number of responding cells remained unchanged upon a further increase in the CCK-8 concen tration (data not shown). In each experiment, the number of cells responding to 10 nM CCK-8 was set at 100%, to which all other values were correlated. These cells are referred to as CCK-8-recruitable ceils. Similarly to the wild-type receptor, cells transfected with the mutant S 139A receptor ( Fig. 3. upper right) or the mutant S379A receptor ( Fig. 3, lower left) were recruited by CCK-8 in a dose-de pendent manner (EC50 values of 61 pM and 101 pM, respectively). Both E C sn values did not significantly differ from that obtained with the wild-type receptor, neither did the number of CCK-8-recruitable cells. In contrast, the EC50 value obtained with the mutant N349A receptor was 80-fold increased to 6.2 nM (Fig. 3, lower right) . The latter value was calculated under the assumption that with higher CCK-8 concentrations the 100% value would be reached.
Devazepide (3 nM), when added 1 min prior to stimula tion with CCK-8, caused the dose-recruitment curve of cells transfected with the wild type CCKA receptor to shift to the right (Fig. 3, upper left) . The EC5() value was calculated to be increased 19-fold to a value of 1,5 nM. With the mutant S379A receptor an even higher (50-fold) increase in the EC5() value was observed to a value of 5.1 nM (Fig. 3, lower left) . By contrast, cells transfected with the mutant S139A receptor were relatively insensitive to 3 nM devazepide (Fig, 3, upper right) . The EC5() value was calculated to be 0.13 nM, representing a 2-fold increase only. The EC50 value obtained with the mutant N349A receptor remained virtually unchanged in the presence of the receptor antagonist (EC5() values of 6.2 nM and 6.9 nM CCK-8 in the absence and presence of 3 nM devazepide, respectively) ( Fig. 3, lower right) . Again, both values were calculated under the assumption that with higher CCK-8 concentrations the 100% value would be reached. Unfortu nately, such higher CCK-8 concentrations could not be tested since they evoked a rise in [Ca2'h] j in part of the non-transfected CHO cells. The latter response was po tently inhibited by devazepide suggesting the involvement of a CCKa type of receptor. Fig. 4 , in which for each single CCK-8 concentration the number of cells respond ing in the presence of devazepide is expressed as a per centage of that responding in the absence of the antagonist, shows that with the S I39A mutant devazepide did not affect the number of ceils recruited by 0.1 nM CCK-8, whereas with the wild-type receptor and the S379A mutant devazepide inhibited recruitment by 40% and 70%, respec tively. At 0 .1 nM and 1 nM CCK-8, the percentage recruitable cells responding in the presence of devazepide was significantly less with the mutant S379A receptor as compared to the mutant S139A receptor.
Effect o f receptor mutations on the inhibition by devazepide o f the CCK-8-evokecl peak increase in average ICa]j in a suspension o f CHO cells transiently express ing the CCKa receptor
CCK-8 transiently increased the fluorescence emission ratio in a suspension of fura-2-loaded CHO cells trans fected with the wild-type CCK A receptor, reflecting a transient increase in average [Ca21 ]; ([Ca2 f']j av). The peak value of the transient increased with increasing of the CCK-8 concentration to reach a maximum at 10 nM CCK-8 (data not shown), in each experiment, the latter value was set at 100%, to which all other values were correlated. With the wild-type receptor the EC50 value was calculated to be 113 pM ( Table 1) Fig. 3 . n Significantly different from the Want S379A receptor ( P < 0.05). Table 1 Summary of the ECS0 values for the CCK-8-evoked increase in cytosolic free Ca" ' concentration obtained with wild-type and mutant CCKA receptors in cell recruitment studies and cell suspension measurements performed in the absence and presence of devazepide different between cells expressing the wild-type receptor and cells expressing the mutant S139A receptor or the mutant S379A receptor but was reduced by 50% in cells expressing the mutant N349A receptor. With the S I39A mutant the E C 50 value was calculated to be decreased 0.7-foJd to 80 pM, whereas with the S379A mutant this value was calculated to be increased 3.6-fold to 405 pM. With the N349A mutant the E C 50 value was calculated to be increased 73-fold to 8.2 nM, under the assumption, however, that with higher CCK-8 concentrations the 100% value will be reached, Devazepide (3 nM), when added 3 min prior to stimula tion with CCK-8, caused the dose-response curve of cells transfected with the wild-type C C K A receptor to shift to the right. The peak increase obtained with 10 nM CCK-8 was reduced by 60%. Under the assumption that with higher CCK-8 concentrations the 100% value will be reached, the EC50 value was calculated to be increased 228-fold to 25.8 nM (Table 1) . With the mutant S379A receptor the peak increase obtained with 10 nM CCK-8 was reduced by 75% and the E C 50 value was calculated to be increased 667-fold to 0.27 jjlM. With the mutant S I39A receptor the peak increase obtained with 10 nM CCK-8 was reduced by 40% and the E C 50 value was calculated to be 4.6 nM, representing a 58-fold increase only. De vazepide effectively inhibited the CCK-8-induced peak increase in [Ca2+]itliv in cells expressing the mutant N349A receptor. In the latter cells the peak increase obtained with 10 nM CCK-8 was reduced by 85% and the E C 50 value was calculated to be increased 80-fold to 0.66 jxM.
Discussion
The aim of the present study was to investigate by site-directed mutagenesis the possible involvement of the hydrophilic residues S er139, Asn349 and Ser379 in the bind ing of the C C K A receptor antagonist devazepide. Func 325 (1997) 93-99 tional characteristics of the three mutants were compared to the wild-type receptor in three experimental setups, (i) inhibition of radioligand binding, (ii) inhibition of the CCK-8-evoked increase in [Ca2+]iav in a suspension of cells, and (iii) inhibition of CCK-8-evoked recruitment of individual cells in terms of receptor-mediated Ca2+ mobi lization.
IIL.L Smeets et al. / European Journal of Pharmacology
In radioligand binding studies replacing Ser139 by ala nine slightly reduced devazepide binding. In contrast, the S379A mutation appeared to increase the affinity of de vazepide for the C C K a receptor* Although the IC 50 values obtained with both mutants did not statistically differ from the value obtained with the wild-type receptor, they did so from one another. With the N349A mutant both agonist and antagonist binding were drastically decreased, suggesting that this amino acid may be important in proper receptor expression.
In addition to studying the effect of the receptor muta tions on the ability of devazepide to displace radiolabelled CCK-8 in a membrane preparation, we investigated the effect of these mutations on the ability of devazepide to inhibit the process of receptor-mediated Ca2+ mobilization in intact cells, Basically, the same results were obtained with both approaches. Thus, compared to the wild-type receptor devazepide inhibited CCK-8-evoked Ca2 + mobi lization less effective with the mutant S139A and N349A receptor and more effective with the mutant S379A recep tor. From the observation that the receptor mutations af fected the ability of devazepide to displace radiolabelled CCK-8 in a membrane preparation and inhibit the process of receptor-mediated Ca2+ mobilization in intact cells in the same way it can be concluded that these mutations did not inteifere with the process of signal transduction.
Beside suspension measurements we performed cell recruitment studies to analyse the effect of receptor muta tions on devazepide inhibition of receptor-mediated Ca2 + mobilization. The advantage of this approach, which is based on the observation that agonists dose-dependently increase the number of responding cells (Willems et al., 1993a (Willems et al., , 1995 Smeets et al.s 1996) , is that only cells that express the receptor are included. The present study shows that with CHO cells transiently expressing the CCK A receptor a transfection efficiency of close to 70% can be reached. Another benefit of this approach is that cells grown on coverslips do not have to be isolated and there fore are not at risk of being exposed to conditions that might damage the receptor. The present study clearly demonstrates that this approach can be of use to analyse the effect of receptor mutations on the relative ability of antagonists to inhibit agonist-evoked Ca2+ mobilization.
The data presented are in agreement with the idea that the three amino acids investigated in this study form part of the putative antagonist binding site, though most proba bly none of them in the role of hydrogen acceptor. This is the first report on the use of mutant receptors to address the antagonist binding site of the C C K A receptor. However, the importance of two other amino acids form ing part of the proposed antagonist binding site in de vazepide binding was recently demonstrated in a study in which CCKB receptor amino acids were replaced by the corresponding amino acids from the CCKA reccptor (Kopin et al., 1995; Jagerschmidt et al., 1996) . For instance, when His381 in the rat C C K B receptor and its equivalent on position 376 in the human CCKB receptor were mutated to leucine, the corresponding amino acid on position 372 in the CCKA receptor, the affinity for devazepide was in creased (Kopin et al" 1995; Jagerschmidt et al., 1996) . Similarly, when Val349 in the human CCK B receptor and its equivalent on position 353 (position 354 according to Wank et al., 1992) in the rat C C K B receptor were mutated to isoleucine, the corresponding amino acid on position 345 in the CCKA receptor, devazepide binding was in creased (Kopin et al., 1995; Beinborn et al., 1993; Malatynska et al., 1995) . This suggests that these two amino acids, lie345 and Leu372, form indeed part of the proposed devazepide binding site. In the same way, the involvement of the amino acids T hrl3\ Gin225 and Phe346, located close to the proposed antagonist binding site in the rat CCKa receptor, in devazepide binding was demon strated (Kopin et al., 1995) . Thus far, only one CCK receptor mutation has been described (Arg57 changed to its corresponding amino acid Gin59 in the rat CCKa receptor) outside the proposed CCKa receptor antagonist binding site that affected devazepide binding (Kopin et al., 1995) .
Taken together the data reported in the literature and those obtained in the present study are in agreement with the proposed antagonist binding site of the CCKA receptor. B
